Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2021 06:00 ET | Source: AC Immune SA

AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases

LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
November 02, 2021 07:30 ET | Source: AC Immune SA

New Data on AC Immune’s Abeta and pTau Clinical Programs in Alzheimer’s Disease To Be Presented at CTAD 2021

LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
October 29, 2021 06:00 ET | Source: AC Immune SA

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a leading...
October 25, 2021 07:00 ET | Source: AC Immune SA

AC Immune to Present at the Jefferies London Healthcare Conference

LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
September 03, 2021 07:52 ET | Source: AC Immune SA

AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year

LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
September 02, 2021 07:00 ET | Source: AC Immune SA

AC Immune to Participate in Upcoming Virtual Investor Conferences in September

LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
August 31, 2021 07:30 ET | Source: AC Immune SA

AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11 First evidence of clinical...
August 04, 2021 07:00 ET | Source: AC Immune SA

AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Announced strategic acquisition of industry-leading Parkinson’s disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE ACI-24 full Phase 1b results...
July 29, 2021 07:30 ET | Source: AC Immune SA

AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021

ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS) Full Phase 1b results support the continued clinical development...
July 27, 2021 07:30 ET | Source: AC Immune SA

AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

All-stock transaction maintains AC Immune’s strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune’s...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right